Overview

* The clinical-stage biotechnology firm focused on gene therapy posts Q2 net loss of $70.9 mln vs $53.0 mln last year

* Q2 revenues dip to $21.4 mln, mainly due to lower Zolgensma royalties

Outlook

* Regenxbio ( RGNX ) anticipates cash runway into early 2027

Result Drivers

* RGX-202 PROGRESS - Accelerated pivotal trial enrollment for Duchenne muscular dystrophy, expected to complete by October 2025

* ZOLGENSMA ROYALTY DECLINE - Revenue decrease mainly attributed to lower Zolgensma royalties, partially offset by Nippon Shinyaku partnership service revenues

* INCREASED R&D EXPENSES - Higher costs due to manufacturing and clinical trials for sura-vec and RGX-202

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $18.46

License mln

&

Royalty

Revenue

Q2 Net -$70.87

Income mln

Q2 $84.64

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Regenxbio Inc ( RGNX ) is $31.50, about 73.9% above its August 6 closing price of $8.23

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)